エピラツズマブ
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/12/11 10:57:39」(JST)
[Wiki en表示]
Epratuzumab?
| Monoclonal antibody |
| Type |
Whole antibody |
| Source |
Humanized (from mouse) |
| Target |
CD22 |
| Clinical data |
| Trade names |
LymphoCide |
| Legal status |
|
| Identifiers |
| CAS Number |
205923-57-5 N |
| ATC code |
None |
| PubChem |
SID: 47206001 |
| IUPHAR/BPS |
8088 |
| DrugBank |
DB04958 N |
| UNII |
3062P60MH9 Y |
| KEGG |
D04036 Y |
|
| N (what is this?) (verify) |
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).[1][2]
Clinical trials
A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results.[3]
Results have been published for a phase II trial in untreated follicular lymphoma.[3]
Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging.[3][4]
The manufacturers in August 2009 announced success in early trials against SLE,[5] and started two Phase III clinical trials.
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.[6]
Mechanism of action
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.
Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system"[6] via a process called trogocytosis.[3] (Other SLE therapies destroy B-cells which compromises the immune system.)
References
- ^ Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1, 2003 free full text
- ^ Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research Vol. 11, July 15, 2005 free full text
- ^ a b c d Epratuzumab
- ^ Micallef et al. (2011). "Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma." (PDF). Blood. 2011 Oct 13;118(15):4053-61. Epub 2011 Jun 14. doi:10.1182/blood-2011-02-336990.
- ^ Reuters: UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)
- ^ a b Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket. July 28 2015
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
- Raetz EA1, Cairo MS2, Borowitz MJ3, Lu X4, Devidas M4, Reid JM5, Goldenberg DM6, Wegener WA6, Zeng H4, Whitlock JA7, Adamson PC8, Hunger SP8, Carroll WL9.
- Pediatric blood & cancer.Pediatr Blood Cancer.2015 Jul;62(7):1171-5. doi: 10.1002/pbc.25454. Epub 2015 Mar 2.
- BACKGROUND: Given the success of immunotherapeutic approaches in hematologic malignancies, the COG designed a phase I/II study to determine whether the addition of epratuzumab (anti-CD22) to an established chemotherapy platform improves rates of second remission (CR2) in pediatric patients with B-ly
- PMID 25732247
- Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
- Chevallier P1, Huguet F2, Raffoux E3, Etienne A4, Leguay T5, Isnard F6, Robillard N7, Guillaume T8, Delaunay J8, Charbonnier A4, Pigneux A5, Peterlin P8, Bené MC7, Wegener WA9, Goldenberg DM9, Dombret H3.
- Haematologica.Haematologica.2015 Apr;100(4):e128-31. doi: 10.3324/haematol.2014.120220. Epub 2014 Dec 31.
- PMID 25552705
- Current status of antibody therapy in ALL.
- Ai J1, Advani A.
- British journal of haematology.Br J Haematol.2015 Feb;168(4):471-80. doi: 10.1111/bjh.13205. Epub 2014 Nov 10.
- Despite the significant advances in modern chemotherapy, it remains challenging to treat adult patients with acute lymphoblastic leukaemia (ALL). The relapse rate remains high, and the outcome at the time of relapse is dismal. Antibody-based therapies have demonstrated promising results in this pati
- PMID 25382151
Japanese Journal
- 次世代の分子ターゲット(第8回)CD20/CD22
- 急性リンパ芽球性白血病に対して臨床試験実施中の抗体薬 : 抗CD22ADCとblinatumomab (特集 血液腫瘍に対する抗体医薬のさらなる進展)
Related Links
- Epratuzumab is a humanized monoclonal antibody targeting CD22 receptors on B lymphocytes. It is being evaluated for the treatment of non-Hodgkin’s lymphoma, and for autoimmune diseases such as systemic lupus ...
- epratuzumab brivaracetam Financials Key figures Full year overview Half-year overview Annual reports Annual reports 2005-2009 Annual reports 2000-2004 Interim reports Financials 2013 Financials 2012 Financials 2011 Bonds ...
★リンクテーブル★
[★]
- 関
- モノクローナル抗体
mab